Intact fibroblast growth factor 23 levels predict incident cardiovascular event before but not after the start of dialysis

Bone

Volumn 50, Issue 6, 2012, Pages 1266-1274

  Nakano, Chikako ^a   Hamano, Takayuki ^a,b   Fujii, Naohiko ^c   Obi, Yoshitsugu ^a   Matsui, Isao ^a   Tomida, Kodo ^d   Mikami, Satoshi ^e   Inoue, Kazunori ^a   Shimomura, Akihiro ^a   Nagasawa, Yasuyuki ^a   Okada, Noriyuki ^f   Tsubakihara, Yoshiharu ^f   Rakugi, Hiromi ^a   Isaka, Yoshitaka ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c Hyogo Prefectural Nishinomiya Hospital   (Japan)

^d KANSAI ROSAI HOSPITAL   (Japan)

^e Higashi Kohri Hospital   (Japan)

^f OSAKA GENERAL MEDICAL CENTER   (Japan)

Author keywords

Cardiovascular disease; Chronic kidney disease; Fibroblast growth factor 23; Mineral metabolism; Risk stratification

Indexed keywords

25 HYDROXYVITAMIN D; ALKALINE PHOSPHATASE; FIBROBLAST GROWTH FACTOR 23; PARATHYROID HORMONE;

ADULT; AGE; ARTICLE; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; DIABETES MELLITUS; DIALYSIS; FEMALE; FOLLOW UP; GENDER; GLOMERULUS FILTRATION RATE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTPATIENT; PREDICTION; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; PULSE PRESSURE;

AGED; ALKALINE PHOSPHATASE; BIOLOGICAL MARKERS; BONE DISEASES, METABOLIC; CARDIOVASCULAR DISEASES; COHORT STUDIES; FEMALE; FIBROBLAST GROWTH FACTORS; GLOMERULAR FILTRATION RATE; HUMANS; JAPAN; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PARATHYROID HORMONE; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RENAL DIALYSIS; TIME FACTORS; VITAMIN D;

EID: 84860840465     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2012.02.634     Document Type: Article

References (64)

1. Moe S., Drueke T., Cunningham J., Goodman W., Martin K., Olgaard K., et al. Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2006, 69:1945-1953.
2. Wolf M., Shah A., Gutierrez O., Ankers E., Monroy M., Tamez H., et al. Vitamin D levels and early mortality among incident hemodialysis patients. Kidney Int 2007, 72:1004-1013.
3. Block G.A., Klassen P.S., Lazarus J.M., Ofsthun N., Lowrie E.G., Chertow G.M. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004, 15:2208-2218.
4. Kestenbaum B., Sampson J.N., Rudser K.D., Patterson D.J., Seliger S.L., Young B., et al. Serum phosphate levels and mortality risk among people with chronic kidney disease. J Am Soc Nephrol 2005, 16:520-528.
5. Voormolen N., Noordzij M., Grootendorst D.C., Beetz I., Sijpkens Y.W., van Manen J.G., et al. High plasma phosphate as a risk factor for decline in renal function and mortality in pre-dialysis patients. Nephrol Dial Transplant 2007, 22:2909-2916.
6. Ravani P., Malberti F., Tripepi G., Pecchini P., Cutrupi S., Pizzini P., et al. levels and patient outcome in chronic kidney disease. Kidney Int 2009, 75:88-95.
7. Mehrotra R., Kermah D.A., Salusky I.B., Wolf M.S., Thadhani R.I., Chiu Y.W., et al. Chronic kidney disease, hypovitaminosis D, and mortality in the United States. Kidney Int 2009, 76:977-983.
8. Pilz S., Tomaschitz A., Friedl C., Amrein K., Drechsler C., Ritz E., et al. Vitamin D status and mortality in chronic kidney disease. Nephrol Dial Transplant 2011, 26:3603-3609.
9. Kovesdy C.P., Ahmadzadeh S., Anderson J.E., Kalantar-Zadeh K. Secondary hyperparathyroidism is associated with higher mortality in men with moderate to severe chronic kidney disease. Kidney Int 2008, 73:1296-1302.
10. Meisinger C., Doring A., Lowel H. Chronic kidney disease and risk of incident myocardial infarction and all-cause and cardiovascular disease mortality in middle-aged men and women from the general population. Eur Heart J 2006, 27:1245-1250.
11. Al Suwaidi J., Reddan D.N., Williams K., Pieper K.S., Harrington R.A., Califf R.M., et al. Prognostic implications of abnormalities in renal function in patients with acute coronary syndromes. Circulation 2002, 106:974-980.
12. Bhuriya R., Li S., Chen S.C., McCullough P.A., Bakris G.L. Plasma parathyroid hormone level and prevalent cardiovascular disease in CKD stages 3 and 4: an analysis from the Kidney Early Evaluation Program (KEEP). Am J Kidney Dis 2009, 53:S3-S10.
13. Schoppet M., Shanahan C.M. Role for alkaline phosphatase as an inducer of vascular calcification in renal failure?. Kidney Int 2008, 73:989-991.
14. Shantouf R., Kovesdy C.P., Kim Y., Ahmadi N., Luna A., Luna C., et al. Association of serum alkaline phosphatase with coronary artery calcification in maintenance hemodialysis patients. Clin J Am Soc Nephrol 2009, 4:1106-1114.
15. Regidor D.L., Kovesdy C.P., Mehrotra R., Rambod M., Jing J., McAllister C.J., et al. Serum alkaline phosphatase predicts mortality among maintenance hemodialysis patients. J Am Soc Nephrol 2008, 19:2193-2203.
16. Kovesdy C.P., Ureche V., Lu J.L., Kalantar-Zadeh K. Outcome predictability of serum alkaline phosphatase in men with pre-dialysis CKD. Nephrol Dial Transplant 2010, 25:3003-3011.
17. Drechsler C., Verduijn M., Pilz S., Krediet R.T., Dekker F.W., Wanner C., et al. Bone alkaline phosphatase and mortality in dialysis patients. Clin J Am Soc Nephrol 2011, 6:1752-1759.
18. Komaba H., Fukagawa M. FGF23-parathyroid interaction: implications in chronic kidney disease. Kidney Int 2010, 77:292-298.
19. Seiler S., Heine G.H., Fliser D. Clinical relevance of FGF-23 in chronic kidney disease. Kidney Int Suppl 2009, S34-S42.
20. Gutierrez O., Isakova T., Rhee E., Shah A., Holmes J., Collerone G., et al. Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. J Am Soc Nephrol 2005, 16:2205-2215.
21. Gutierrez O.M., Januzzi J.L., Isakova T., Laliberte K., Smith K., Collerone G., et al. Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease. Circulation 2009, 119:2545-2552.
22. Yilmaz M.I., Sonmez A., Saglam M., Yaman H., Kilic S., Demirkaya E., et al. FGF-23 and vascular dysfunction in patients with stage 3 and 4 chronic kidney disease. Kidney Int 2010, 78:679-685.
23. Blacher J., Guerin A.P., Pannier B., Marchais S.J., London G.M. Arterial calcifications, arterial stiffness, and cardiovascular risk in end-stage renal disease. Hypertension 2001, 38:938-942.
24. Goodman W.G., London G., Amann K., Block G.A., Giachelli C., Hruska K.A., et al. Vascular calcification in chronic kidney disease. Am J Kidney Dis 2004, 43:572-579.
25. Levin A., Singer J., Thompson C.R., Ross H., Lewis M. Prevalent left ventricular hypertrophy in the predialysis population: identifying opportunities for intervention. Am J Kidney Dis 1996, 27:347-354.
26. Seiler S., Reichart B., Roth D., Seibert E., Fliser D., Heine G.H. FGF-23 and future cardiovascular events in patients with chronic kidney disease before initiation of dialysis treatment. Nephrol Dial Transplant 2010, 25:3983-3989.
27. Tanaka H., Hamano T., Fujii N., Tomida K., Matsui I., Mikami S., et al. The impact of diabetes mellitus on vitamin D metabolism in predialysis patients. Bone 2009, 45:949-955.
28. Matsuo S., Imai E., Horio M., Yasuda Y., Tomita K., Nitta K., et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 2009, 53:982-992.
29. Weber T.J., Liu S., Indridason O.S., Quarles L.D. Serum FGF23 levels in normal and disordered phosphorus homeostasis. J Bone Miner Res 2003, 18:1227-1234.
30. Donders A.R., van der Heijden G.J., Stijnen T., Moons K.G. Review: a gentle introduction to imputation of missing values. J Clin Epidemiol 2006, 59:1087-1091.
31. Pencina M.J., D'Agostino R.B., D'Agostino R.B., Vasan R.S. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med 2008, 27:157-172.
32. Pencina M.J., D'Agostino R.B., Steyerberg E.W. Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers. Stat Med 2011, 30:11-21.
33. Janes H., Pepe M.S., Gu W. Assessing the value of risk predictions by using risk stratification tables. Ann Intern Med 2008, 149:751-760.
34. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003, 42:S1-S201.
35. de Boer I.H., Kestenbaum B., Shoben A.B., Michos E.D., Sarnak M.J., Siscovick D.S. 25-hydroxyvitamin D levels inversely associate with risk for developing coronary artery calcification. J Am Soc Nephrol 2009, 20:1805-1812.
36. de Zeeuw D., Agarwal R., Amdahl M., Audhya P., Coyne D., Garimella T., et al. Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial. Lancet 2010, 376:1543-1551.
37. Goto S., Fujii H., Hamada Y., Yoshiya K., Fukagawa M. Association between indoxyl sulfate and skeletal resistance in hemodialysis patients. Ther Apher Dial 2010, 14:417-423.
38. Fahrleitner-Pammer A., Herberth J., Browning S.R., Obermayer-Pietsch B., Wirnsberger G., Holzer H., et al. Bone markers predict cardiovascular events in chronic kidney disease. J Bone Miner Res 2008, 23:1850-1858.
39. Urena P., Bernard-Poenaru O., Cohen-Solal M., de Vernejoul M.C. Plasma bone-specific alkaline phosphatase changes in hemodialysis patients treated by alfacalcidol. Clin Nephrol 2002, 57:261-273.
40. Kovesdy C.P., Ahmadzadeh S., Anderson J.E., Kalantar-Zadeh K. Association of activated vitamin D treatment and mortality in chronic kidney disease. Arch Intern Med 2008, 168:397-403.
41. Kendrick J., Cheung A.K., Kaufman J.S., Greene T., Roberts W.L., Smits G., et al. FGF-23 associates with death, cardiovascular events, and initiation of chronic dialysis. J Am Soc Nephrol 2011, 22:1913-1922.
42. Imel E.A., Peacock M., Pitukcheewanont P., Heller H.J., Ward L.M., Shulman D., et al. Sensitivity of fibroblast growth factor 23 measurements in tumor-induced osteomalacia. J Clin Endocrinol Metab 2006, 91:2055-2061.
43. Larsson T., Nisbeth U., Ljunggren O., Juppner H., Jonsson K.B. Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers. Kidney Int 2003, 64:2272-2279.
44. Matsushita K., van der Velde M., Astor B.C., Woodward M., Levey A.S., de Jong P.E., et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet 2010, 375:2073-2081.
45. Shimada T., Kakitani M., Yamazaki Y., Hasegawa H., Takeuchi Y., Fujita T., et al. Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. J Clin Invest 2004, 113:561-568.
46. Burnett S.M., Gunawardene S.C., Bringhurst F.R., Juppner H., Lee H., Finkelstein J.S. Regulation of C-terminal and intact FGF-23 by dietary phosphate in men and women. J Bone Miner Res 2006, 21:1187-1196.
47. Ferrari S.L., Bonjour J.P., Rizzoli R. Fibroblast growth factor-23 relationship to dietary phosphate and renal phosphate handling in healthy young men. J Clin Endocrinol Metab 2005, 90:1519-1524.
48. Nishida Y., Taketani Y., Yamanaka-Okumura H., Imamura F., Taniguchi A., Sato T., et al. Acute effect of oral phosphate loading on serum fibroblast growth factor 23 levels in healthy men. Kidney Int 2006, 70:2141-2147.
49. Koh N., Fujimori T., Nishiguchi S., Tamori A., Shiomi S., Nakatani T., et al. Severely reduced production of klotho in human chronic renal failure kidney. Biochem Biophys Res Commun 2001, 280:1015-1020.
50. Urakawa I., Yamazaki Y., Shimada T., Iijima K., Hasegawa H., Okawa K., et al. Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature 2006, 444:770-774.
51. Kuro-o M. Overview of the FGF23-Klotho axis. Pediatr Nephrol 2010, 25:583-590.
52. Hu M.C., Shi M., Zhang J., Quinones H., Griffith C., Kuro-o M., et al. Klotho deficiency causes vascular calcification in chronic kidney disease. J Am Soc Nephrol 2011, 22:124-136.
53. Ikushima M., Rakugi H., Ishikawa K., Maekawa Y., Yamamoto K., Ohta J., et al. Anti-apoptotic and anti-senescence effects of Klotho on vascular endothelial cells. Biochem Biophys Res Commun 2006, 339:827-832.
54. Rakugi H., Matsukawa N., Ishikawa K., Yang J., Imai M., Ikushima M., et al. Anti-oxidative effect of Klotho on endothelial cells through cAMP activation. Endocrine 2007, 31:82-87.
55. Kardami E., Jiang Z.S., Jimenez S.K., Hirst C.J., Sheikh F., Zahradka P., et al. Fibroblast growth factor 2 isoforms and cardiac hypertrophy. Cardiovasc Res 2004, 63:458-466.
56. Faul C., Amaral A.P., Oskouei B., Hu M.C., Sloan A., Isakova T., et al. FGF23 induces left ventricular hypertrophy. J Clin Invest 2011, 121:4393-4408.
57. Parker B.D., Schurgers L.J., Brandenburg V.M., Christenson R.H., Vermeer C., Ketteler M., et al. The associations of fibroblast growth factor 23 and uncarboxylated matrix Gla protein with mortality in coronary artery disease: the Heart and Soul Study. Ann Intern Med 2010, 152:640-648.
58. Gutierrez O.M., Mannstadt M., Isakova T., Rauh-Hain J.A., Tamez H., Shah A., et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med 2008, 359:584-592.
59. Imanishi Y., Inaba M., Nakatsuka K., Nagasue K., Okuno S., Yoshihara A., et al. FGF-23 in patients with end-stage renal disease on hemodialysis. Kidney Int 2004, 65:1943-1946.
60. Isakova T., Xie H., Barchi-Chung A., Vargas G., Sowden N., Houston J., et al. Fibroblast growth factor 23 in patients undergoing peritoneal dialysis. Clin J Am Soc Nephrol 2011, 6:2688-2695.
61. Jean G., Terrat J.C., Vanel T., Hurot J.M., Lorriaux C., Mayor B., et al. High levels of serum fibroblast growth factor (FGF)-23 are associated with increased mortality in long haemodialysis patients. Nephrol Dial Transplant 2009, 24:2792-2796.
62. Weiner D.E., Tighiouart H., Vlagopoulos P.T., Griffith J.L., Salem D.N., Levey A.S., et al. Effects of anemia and left ventricular hypertrophy on cardiovascular disease in patients with chronic kidney disease. J Am Soc Nephrol 2005, 16:1803-1810.
63. Soriano S., Gonzalez L., Martin-Malo A., Rodriguez M., Aljama P. C-reactive protein and low albumin are predictors of morbidity and cardiovascular events in chronic kidney disease (CKD) 3-5 patients. Clin Nephrol 2007, 67:352-357.
64. Shara N.M., Wang H., Valaitis E., Pehlivanova M., Carter E.A., Resnick H.E., et al. Comparison of estimated glomerular filtration rates and albuminuria in predicting risk of coronary heart disease in a population with high prevalence of diabetes mellitus and renal disease. Am J Cardiol 2011, 107:399-405.